Status and phase
Conditions
Treatments
About
Objective:
Primary objective of the present study was to compare the single dose bioavailability of Torrent's Felodipine Extended-Release Tablets USP 10 mg and Innovator's (Mylan Pharmaceuticals Inc., USA) Felodipine Extended-Release Tablets USP 10 mg. Dosing periods were separated by a washout period of 21 days during fasting study.
Study Design:
Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study
Sex
Ages
Volunteers
Inclusion criteria
The volunteers were included in the study based on the following criteria:
Exclusion criteria
The volunteers were excluded from the study based on the following criteria:
Pulse rate less than 50/minute or more than 100/minute.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal